GSK and SK Bioscience Initiate P-III Study of GBP510 Against AZ/Oxford’s COVID-19 Vaccine
GSK’s Nucala (mepolizumab) Receives the EC’s Approval for the Treatment of Eosinophil-Driven Diseases
Shots:
- The study will evaluate the safety and immunogenicity of GBP510 vs AZ/Oxford University’s COVID-19 vaccine and will enroll ~ 4,000 participants across multiple countries
- The initiation of the P-III study follows positive interim P-I/II data that showed all participants who received the GBP510 developed strong neutralizing Ab responses, demonstrating a 100% seroconversion rate
- The companies are planning for the global supply of the vaccine through the COVAX facility in the H1’22, subject to positive results and regulatory approval
Click here to read full press release/ article | Ref: GSK | Image: Fierce Pharma